Floatz logo

PEGASPARGASE

B-Cell Adult Acute Lymphocytic Leukemia

National Cancer Institute (NCI)protein_peptidePhase 3Dormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the B-Cell Adult Acute Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Vincristine sulfate
SWOG Cancer Research Network
Phase 3BBB
METHOTREXATE
Massachusetts General Hospital
Phase 3BBB
Dexasone
Mayo Clinic
Phase 3BBB
Cytarabine
Massachusetts General Hospital
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB

View all 50 →

Same molecule, other indications

PEGASPARGASE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative · Phase 3
80 / 100
View asset →
extranodal nasal NK/T cell lymphomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
non-Hodgkin lymphomaDormant
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →